Ramanisblog

Tag: Diseases and Conditions

  • Many Dialysis Patients Undergoing PCI Receive Improper Medication, With Higher Risk of Bleeding

    ScienceDaily (Dec. 11, 2009) — Approximately 20 percent of dialysis patients undergoing a percutaneous coronary intervention (PCI; procedure such as angioplasty) are given an antithrombotic medication they should not receive, which may increase their risk for in-hospital bleeding, according to a study in the December 9 issue of JAMA.
    See Also:

    “In the United States, medication errors are implicated in more than 100,000 deaths annually. Medication errors include adverse drug reactions related to inappropriately prescribed or administered drugs. To minimize inappropriate medication use, the U.S. Food and Drug Administration (FDA) guides pharmaceutical manufacturers and clinicians through drug labeling of which medications are contraindicated or not recommended for use in specific patient groups,” the authors write. “Little is known about the use of such medications and their effects on outcomes in clinical practice.”
    Thomas T. Tsai, M.D., M.Sc., of the Denver VA Medical Center and University of Colorado Denver, and colleagues examined the use of the contraindicated/not-recommended antithrombotic agents enoxaparin and eptifibatide among dialysis patients undergoing percutaneous coronary intervention (PCI) and their association with outcomes. The researchers used data from the National Cardiovascular Data Registry (NCDR) from 829 U.S. hospitals on 22,778 dialysis patients who underwent PCI between Jan. 2004 and August 2008. The study focused on the outcomes of in-hospital bleeding and death.
    The researchers found that overall, 5,084 patients (22.3 percent) received a contraindicated antithrombotic medication; 2,375 (46.7 percent) received enoxaparin, 3,261 (64.1 percent) received eptifibatide, and 552 (10.9 percent) received both. In unadjusted analysis, patients who received contraindicated antithrombotics experienced higher rates of in-hospital major bleeding (5.6 percent vs. 2.9 percent) and death (6.5 percent vs. 3.9 percent). Further analysis indicated that receipt of contraindicated antithrombotics was significantly associated with increased in-hospital major bleeding, but no significant association was found with in-hospital death.
    “This study therefore demonstrates that these medications are used in clinical practice despite FDA-directed labeling, and their use is associated with adverse patient outcomes,” the authors write.
    “Educational efforts targeting clinicians who prescribe these medications and quality improvement interventions, such as amending clinical pathway order sets to include consideration of renal function, are urgently needed.”

  • Hope for Patients With Type 2 Diabetes

    Story:
    ScienceDaily (Dec. 4, 2009) — The outlook for individuals with type 2 diabetes and coronary artery disease is not as grim as originally believed, according to new Saint Louis University research published in Circulation, the Journal of the American Heart Association.
    See Also:
    Health & Medicine

    “Our research found that people with type 2 diabetes and heart disease have a more favorable prognosis with proper medical care and management of risk factors, including cholesterol, blood pressure, high blood sugar levels and smoking than previously thought,” said Bernard R. Chaitman, M.D., professor of medicine and cardiologist at Saint Louis University School of Medicine and a lead investigator of the study.
    “This goes against common beliefs among many physicians that these patients die most commonly of cardiac causes and gives us a lot of hope.”
    The goal of the Bypass Angioplasty Revasularization Investigation 2 Diabetes (BARI 2D) trial was to examine how deadly heart disease is in individuals with type 2 diabetes and to identify the best treatment options for these patients, including whether artery revascularization via an angioplasty procedure or bypass surgery is necessary.
    In total, 2.368 study participants were followed for five years. All study participants received the treatment recommended by their physician, as well as intensive medical therapy, including medication for cholesterol, blood pressure, diabetes, and lifestyle changes such as weight management and smoking cessation counseling.
    The research found that individuals with mild to moderate coronary heart disease, who were treated with intensive medical therapy alone, were no more likely to die from a heart problem after five years than those who also had an angioplasty procedure, which clears artery blockage by inserting a balloon in the artery and then inflating it. After five years, 4 to 5 percent of these patients died from a heart attack or related heart disease.
    For individuals with more extensive heart disease, however, coronary bypass surgery, in addition to intensive medical therapy, significantly decreased the risk of heart attacks and cardiac-related deaths. Sixteen percent of patients who received bypass surgery either died or had a heart attack within five years compared to 22 percent of patients who received intensive medical therapy alone.
    According to Chaitman, individuals with more severe and extensive coronary blockage are more likely to experience a heart attack without prompt bypass surgery. Heart attacks increase the risk of death five to eight times more than in individuals without a heart attack .
    “Our primary goal always is to prevent heart attacks from occurring; however, our research found that angioplasty is not always necessary in preventing a heart attack or cardiac-related death just because a blocked artery is present. Patients with type 2 diabetes and heart disease need to have a frank discussion with their doctors about their treatment options and what’s best for their individual case,” Chaitman said.
    The BARI 2D trial was funded by the national Heart, Lung and Blood Institute and the National Institute of Diabetes and Digestive and Kidney Diseases.
    Study co-authors include Regina M Hardison, M.S., (University of Pittsburgh), Dale Adler, M.D., (Brigham and Women’s Hospital), Suzanne Gebhart, M.D., (Emory University), Mary Grogan, R.N., (Brown University), Salvador Ocampo, M.D., (Mexican Institute of Social Security in Mexico), George Sopko, M.D., (National Institutes of Health); Jose A. Ramires, M.D., (University of Sao Paula Heart Institute in Brazil), David Schneider, M.D., (University of Vermont) and Robert L. Frye, M.D., (Mayo Clinic).
    http://www.sciencedaily.com/releases/2009/12/091203091910.htm